Stonepine Capital Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Stonepine Capital Management’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-374,431	Closed	-$3.47M	–	26
2020 Q1	$3.47M	Sell	374,431 -256,431	-41%	-$3.58M	3.67%	11
2019 Q4	$10.5M	Sell	630,862 -50,950	-7%	-$826K	7.3%	4
2019 Q3	$11.3M	Buy	681,812 +453,912	+199%	+$6.28M	11.01%	2
2019 Q2	$3.14M	Buy	227,900 +100,676	+79%	+$1.54M	2.16%	17
2019 Q1	$2.19M	Sell	127,224 -95,097	-43%	-$1.5M	1.26%	21
2018 Q4	$2.84M	Sell	222,321 -3,556	-2%	-$53.9K	2.5%	15
2018 Q3	$3.67M	Buy	+225,877	New	+$3.23M	2.14%	13
2018 Q2	–	Sell	-263,974	Closed	-$3.29M	–	34
2018 Q1	$3.29M	Buy	+263,974	New	+$3.21M	1.76%	16
2017 Q4	–	Sell	-162,286	Closed	-$2.73M	–	33
2017 Q3	$2.73M	Buy	+162,286	New	+$2.64M	1.61%	17

Other funds holding OXFD

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Stonepine Capital Management's OXFD Position: Q2 2020 in Review

Stonepine Capital Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2020, closing a stake of 374,431 shares — an estimated $3.47M sold.

Stonepine Capital Management first reported a position in OXFD in Q3 2017 and held it in 9 quarters. The position peaked at $11.3M in Q3 2019. 65 funds tracked by Wall St. Rank hold OXFD as of Q2 2020.

Stonepine Capital Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2020 after selling out during the quarter.
Stonepine Capital Management sold 374,431 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2020, an estimated $3.47M.
Stonepine Capital Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q3 2017 and held it in 9 quarters.
Stonepine Capital Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $11.3M in Q3 2019.
65 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2020.

Based on Stonepine Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.